Herantis Pharma Plc’s nomination of Vice Chairman

Herantis Pharma Plc
Company release 31 May 2019 at 8:00 am

Herantis Pharma Plc’s nomination of Vice Chairman

Herantis Pharma Plc
Company release 31 May 2019 at 8:00 AM

The Board of Directors of Herantis Pharma Plc has nominated Timo Veromaa as its Vice Chairman.

Further information:

Herantis Pharma Plc, Pekka Simula, CEO, telephone: +358 40 7300 445
Company web site: www.herantis.com
Certified Advisor: UB Securities Ltd, telephone: +358 9 25 380 225

About Herantis Pharma Plc

Herantis Pharma Plc is an innovative drug development company focused on regenerative medicine and unmet clinical needs. Our clinical stage assets CDNF and Lymfactin® are based on globally leading scientific research in their fields. They both aim at breakthrough in the treatment of severe diseases: CDNF in neurodegenerative diseases such as Parkinson’s disease; and Lymfactin® in breast cancer associated lymphedema with potential also in other lymphedemas. The shares of Herantis are listed on the First North Finland marketplace run by Nasdaq Helsinki stock exchange.

Distribution:

Nasdaq Helsinki
Main media
www.herantis.com